

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
13407-026US1Application No.
10/538,823**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.98(b))

Applicant
Elixir Pharmaceuticals, Inc.Filing Date
June 13, 2005Group Art Unit
1656**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AI	WO 98/58541	12/30/1998	PCT	G01N33	53		
	AJ							
	AK							
	AL							
	AM							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AN	Cheong et al., "Induction of Apoptosis by Apicidin, a Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways", Cancer Biology & Therapy (United States). September-October 2003, Vol. 2, No. 5, pages 544-551, entire document.
	AO	Marques et al., "Hemeptide Models for Hemoproteins: the Behavior of N-acetylmicroperoxidase-11 in Aqueous Solution", Journal Inorganic Biochemistry 75:281-291, 1999, entire document.
	AP	Rieder et al., "The Cytochrome C Oxidase Binding Site on Cytochrome C: Differential Chemical Modification of Lysine Residues in Free and Oxidase-Bound Cytochrome C", Journal Biological Chemistry 253:6045-6053, September 10, 1978, entire document.
	AQ	Yu et al., "Induction of Apoptosis in BCR/ABL+ Cells by Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways", Cancer Biology & Therapy (United States), 2:544-552, September-October 2003, entire document.

Examiner Signature /Jae W. Lee/ (07/16/2008)	Date Considered 07/16/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JWL/